



## Altamira Therapeutics Announces Expansion of Bentrío License and Distribution Agreement with Nuance Pharma in East and South East Asia

September 16, 2024 12:30 PM EDT

Hamilton, Bermuda, Sept. 16, 2024 (GLOBE NEWSWIRE) --

- Nuance Pharma successfully launched Bentrío® nasal spray for protection against airborne particles in Hong Kong and filed request for marketing authorization for Mainland China
- Extension of Exclusive License and Distribution Agreement to include seven additional countries across East and South East Asia with cumulated population > 630 million

Altamira Therapeutics Ltd. ("Altamira" or the "Company") (Nasdaq:CYTO) today announced that its associate company Altamira Medica Ltd. has agreed with its partner Nuance Pharma, Shanghai, China ("Nuance") to extend the territory covered by their exclusive license and distribution agreement for Bentrío® nasal spray by several countries across South East and East Asia. Under the amended agreement, Nuance's territory will expand from China, Hong Kong, Macau and South Korea to also include Singapore, Malaysia, Thailand, Philippines, Indonesia, Vietnam and Taiwan, with a combined population of greater than 630 million people. Nuance has been marketing Bentrío since late 2022 in Hong Kong and recently submitted the request for marketing approval for Mainland China.

"We are very satisfied with the collaboration with our partner Nuance who has shown great dedication and launched Bentrío successfully in Hong Kong," commented Thomas Meyer, Altamira Medica's Chairman and CEO. "Together with Nuance we look forward to making Bentrío available in further countries, first in the existing license territory and subsequently also in the newly added countries to provide relief to the growing number of allergic rhinitis patients in East and South East Asia."

"We are excited to reinforce and expand our successful collaboration with Altamira on Bentrío," stated Mark G. Lotter, founder and CEO of Nuance Pharma. "Bentrío offers some unique features such as immediate onset and long duration of protection against airborne particles, strong efficacy and good tolerability thanks to its drug-free and preservative-free formulation. They resonate well with medical professionals and consumers, and we look forward to rolling out the product in additional countries and marketing it through our large sales force and growing network of partners."

### About Bentrío

Bentrío is an "over the counter" drug-free nasal spray for personal protection against airborne allergens and, where approved, against airborne viruses. Upon application into the nose, Bentrío forms a protective gel layer on the nasal mucosa. This thin film is designed to prevent the contact of airborne particles with cells; in addition, the composition serves to bind such particles and help with their discharge. The efficacy and safety of Bentrío has been demonstrated in a total of four clinical trials, of which the largest one ("NASAR" study) enrolled 100 patients suffering from seasonal allergic rhinitis. In NASAR, participants self-administered either Bentrío or saline nasal spray for two weeks 3 times per day. The study showed a statistically significant reduction in the mean daily reflective Total Nasal Symptom Score (rTNSS) for Bentrío compared to saline ( $p = 0.013$ ), as well as a statistically highly significant improvement in health-related quality of life (Rhinoconjunctivitis Quality of Life Questionnaire,  $p < 0.001$ ) and superior global ratings of efficacy by patients and investigators alike ( $p < 0.001$ ). In addition, Bentrío showed good safety and tolerability, similar to saline controls, and fewer Bentrío treated patients used relief medication and more of them enjoyed symptom-free days compared to saline treatment. For more information, visit: [www.bentrio.com](http://www.bentrio.com)

### About Altamira Therapeutics

Altamira Therapeutics (Nasdaq: CYTO) is developing and supplying peptide-based nanoparticle technologies for efficient RNA delivery to extrahepatic tissues (OligoPhore™ / SemaPhore™ platforms). The Company currently has two flagship siRNA programs using its proprietary delivery technology AM-401 for KRAS driven cancer and AM-411 for rheumatoid arthritis, both in preclinical development beyond in vivo proof of concept. The versatile delivery platform is also suited for mRNA and other RNA modalities and made available to pharma or biotech companies through out-licensing. In addition, Altamira holds a 49% stake (with additional economic rights) in Altamira Medica AG, which holds its commercial-stage legacy asset Bentrío®, an OTC nasal spray for allergic rhinitis. Further, the Company is in the process of partnering / divesting its inner ear legacy assets. Founded in 2003, Altamira is headquartered in Hamilton, Bermuda, with its main operations in Basel, Switzerland. For more information, visit: <https://altamiratherapeutics.com/>

### About Nuance Pharma

Nuance Pharma is a patient-centric and innovation focused biopharmaceutical company, with both clinical and commercial stage assets. Founded by Mark G. Lotter in 2014, with the mission to address critical unmet medical needs in Greater China and Asia Pacific, Nuance has built a late clinical stage innovative portfolio, while maintaining a self-sustainable commercial operation. Focusing on specialty care, Nuance's portfolio represents a differentiated combination of commercial stage and innovative pipeline assets across respiratory, emergency care, and iron deficiency anemia. For more information, visit: <https://www.nuancepharma.com/>

### Forward-Looking Statements

This press release may contain statements that constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements are statements other than historical facts and may include statements that address future operating, financial or business performance or Altamira's strategies or expectations. In some cases, you can identify these statements by forward-looking words such as "may", "might", "will", "should", "expects", "plans", "anticipates", "believes", "estimates", "predicts", "projects", "potential", "outlook" or "continue", or the negative of these terms or other comparable terminology. Forward-looking statements are based on management's current expectations and beliefs and involve significant risks and uncertainties that could cause actual results, developments and business decisions to differ materially from those contemplated by these statements. These risks and

uncertainties include, but are not limited to, the clinical utility of Altamira's product candidates, the timing or likelihood of regulatory filings and approvals, Altamira's intellectual property position and Altamira's financial position. These risks and uncertainties also include, but are not limited to, those described under the caption "Risk Factors" in Altamira's Annual Report on Form 20-F for the year ended December 31, 2023, and in Altamira's other filings with the Securities Exchange Commission ("SEC"), which are available free of charge on the SEC's website at: [www.sec.gov](http://www.sec.gov). Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those indicated. All forward-looking statements and all subsequent written and oral forward-looking statements attributable to Altamira or to persons acting on behalf of Altamira are expressly qualified in their entirety by reference to these risks and uncertainties. You should not place undue reliance on forward-looking statements. Forward-looking statements speak only as of the date they are made, and Altamira does not undertake any obligation to update them in light of new information, future developments or otherwise, except as may be required under applicable law.

**Investor Contact:**

[Hear@altamiratherapeutics.com](mailto:Hear@altamiratherapeutics.com)